Technology News and Research

RSS

Government officials attend press conference announcing international healthcare service session at 4th CIFTIS

A press conference announcing the hosting of the International Healthcare Service session at the 4th China Beijing International Fair for Trade in Services (CIFTIS), which was co-organized by CiMing Health Checkup Management Group, was held in Beijing on December 18th, 2015.

23 Dec 2015

SuperCom signs definitive agreement to acquire Leaders in Community Alternatives

SuperCom, a global provider of secure solutions for the e-Government, Public Safety, HealthCare, and Finance sectors announced today that it has entered into a definitive agreement to acquire Leaders in Community Alternatives, Inc., a California-based criminal justice organization providing electronic monitoring and community-based services under contracts with various government agencies.

22 Dec 2015

Bern study sheds light on the brain mechanism of arousal

Scientists from Bern have discovered a mechanism which is responsible for the rapid arousal from sleep and anesthesia in the brain. The results of their study suggest new strategies for the medical treatment of sleep disorders and recovery of consciousness in vegetative states.

22 Dec 2015

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

22 Dec 2015

Forge Therapeutics obtains exclusive license to patent rights related to novel metalloprotein inhibitors

Forge Therapeutics, Inc., a biotechnology company developing innovative medicines using a breakthrough drug discovery platform targeting metalloproteins, announced today it has obtained an exclusive license from the University of California San Diego to patent rights related to novel metalloprotein inhibitors discovered in the laboratory of Forge Therapeutics scientific co-founder Professor Seth Cohen, Ph.D.

22 Dec 2015

New MRI-based technology could help identify patients at risk of recurrent stroke

Patients who have had a stroke in the back of the brain are at greater risk of having another within two years if blood flow to the region is diminished, according to results of a multicenter study led by researchers at the University of Illinois at Chicago.

22 Dec 2015

New drug approved by FDA for treatment of von Willebrand disease

"VONVENDI [von Willebrand factor (Recombinant)]", the new drug from Baxalta Incorporated, a global biopharmaceutical company recently spun off from Baxter International, has just been approved by the United States Food and Drug Administration.

22 Dec 2015

Email communications between patients, physicians improve overall health

A third of patients with chronic conditions who exchanged secure emails with their doctors said that these communications improved their overall health, according to a Kaiser Permanente study published today in the American Journal of Managed Care.

22 Dec 2015

Small airway-on-a-chip enables analysis of human COPD and asthma

A research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University leveraged its organ-on-a-chip technology to develop a model of the human small airway in which lung inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), the third leading cause of mortality worldwide, and asthma can be studied outside the human body.

22 Dec 2015

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza Pharmaceuticals, Inc. today announced interim results of its Phase 2a study of AZ-002 (Staccato alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study.

21 Dec 2015

Aquinnah secures $5 million private equity investment from Takeda

Aquinnah Pharmaceuticals announced today that it has received a $5 Million investment from Takeda Pharmaceutical Company, Limited, in it's first private equity financing. The company has assembled a world-class team of drug developers and an exceptional Scientific Advisory Board in the fields of Amyotrophic Lateral Sclerosis (ALS), protein and RNA regulation, and neurodegenerative diseases.

21 Dec 2015

New survey shows how patients, pharmacists benefit from med sync programs

A recent survey of National Community Pharmacists Association member pharmacies utilizing NCPA's Simplify My Meds (SMM) program documented how both patients and pharmacists benefit from medication synchronization programs, or "med sync."

21 Dec 2015

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with Eli Lilly and Company to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE platform.

21 Dec 2015

Chromatrap to be Lead Sponsor at 'Epigenetics in Drug Discovery' conference

Chromatrap, a business unit of Porvair Sciences, has announced that it will be the Lead Sponsor at the prestigious “Epigenetics in Drug Discovery” conference to be held in Cambridge, UK from 26th-27th January 2016.

From Chromatrap® - Porvair Sciences Ltd 21 Dec 2015

Anytime Fitness acquires PumpOne

Anticipating the needs and preferences of current and future gym members, Anytime Fitness announced today that it has purchased PumpOne – a leading mobile personal training services provider featuring the world's largest exercise image and video library.

21 Dec 2015

New study improves understanding of metal-based chemotherapy drugs

What is the mechanism of action of metal-based chemotherapy drugs (the most widely used for treating common cancers like testicular or ovarian cancer)? How can we improve their effect and reduce their toxicity? A new study combining experiments and theory has broadened our knowledge of the molecular mechanisms of these active drugs to help experimentalists devising increasingly effective drugs with fewer side effects.

21 Dec 2015

Roche's cobas HIV-1 viral load test approved by FDA for use on cobas 6800 and cobas 8800 Systems

Roche announced today that it has received FDA approval for the cobas HIV-1 viral load test by the United States Food and Drug Administration for use on the cobas 6800 and cobas 8800 Systems. This HIV-1 viral load test is part of the next generation of Roche viral load tests, which clinicians use to manage the disease and treatment of patients infected with HIV-1.

21 Dec 2015

CMFT adopts ZedScan system to improve cervical cancer care

DP Medical Systems Ltd has secured a deal with Central Manchester University Hospitals NHS Foundation Trust (CMFT) to adopt ZedScan™ as part of its cervical cancer care pathway.

From Zilico 21 Dec 2015

TUM scientists develop small molecule that may allow future patient-specific treatment of cancer tumours

Integrins help cells communicate with and adapt to their environment. Also cancer cells depend on their properties to survive and spread throughout the body. Now scientists at the Technical University of Munich have successfully developed a small, highly active molecule that binds to a specific integrin which operates in many types of cancer.

21 Dec 2015

Certain gut bacteria linked to type 2 diabetes, reveal Russian scientists

A group of Russian scientists, including Dr Elena Kostryukova, the Head of the Laboratory of Postgenomic Research in Biology of the Scientific Research Institute of Physical-Chemical Medicine and a researcher at MIPT (Moscow Institute of Physics and Technology), and Maria Vakhitova, an MIPT postgraduate student, has discovered that the presence of certain bacteria in the gut may be linked to the development of type 2 diabetes.

21 Dec 2015

Technology News and Research

Government officials attend press conference announcing international healthcare service session at 4th CIFTIS

SuperCom signs definitive agreement to acquire Leaders in Community Alternatives

Bern study sheds light on the brain mechanism of arousal

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Forge Therapeutics obtains exclusive license to patent rights related to novel metalloprotein inhibitors

New MRI-based technology could help identify patients at risk of recurrent stroke

New drug approved by FDA for treatment of von Willebrand disease

Email communications between patients, physicians improve overall health

Small airway-on-a-chip enables analysis of human COPD and asthma

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Aquinnah secures $5 million private equity investment from Takeda

New survey shows how patients, pharmacists benefit from med sync programs

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Chromatrap to be Lead Sponsor at 'Epigenetics in Drug Discovery' conference

Anytime Fitness acquires PumpOne

New study improves understanding of metal-based chemotherapy drugs

Roche's cobas HIV-1 viral load test approved by FDA for use on cobas 6800 and cobas 8800 Systems

CMFT adopts ZedScan system to improve cervical cancer care

TUM scientists develop small molecule that may allow future patient-specific treatment of cancer tumours

Certain gut bacteria linked to type 2 diabetes, reveal Russian scientists

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News